project: cardiodx

CardioDX logo

Connect with a Sales Specialist


Press Releases

CardioDx to Present at the 11th Annual Needham Healthcare Conference

PALO ALTO, Calif. – April 2, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Chief Medical Officer Mark Monane, M.D., will present an overview
of the company and of Corus® CAD, the first and only clinically validated gene expression test for obstructive coronary artery disease, at the 11th Annual Needham Healthcare Conference on Tuesday,
April 3 at 10:40 a.m. ET at the New York Palace Hotel.

With a simple blood draw, Corus CAD can help primary care clinicians and cardiologists exclude obstructive coronary artery disease as the cause of a stable non-diabetic patient's symptoms. It is the
first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test has now been used to assess the presence of
obstructive coronary artery disease in more than 25,000 U.S. patients. Corus CAD has been honored as a winner of The Wall Street Journal’s Technology Innovation Awards and one of TIME’s Top Ten Medical Breakthroughs, and is a finalist for the 2012 Edison Awards.

Findings from the PREDICT validation study of the Corus CAD gene expression test were published in 2010 in the Annals of Internal Medicine, the journal of the American College of Physicians. The Corus CAD test measures the RNA levels of 23 genes from a whole blood sample. Because these RNA levels are increased or decreased when obstructive coronary artery disease is present, the Corus CAD score indicates the likelihood that an individual patient does not have obstructive coronary artery disease.

Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif.
laboratory. Test results are delivered promptly to the clinician’s office. Corus CAD is currently available in the United States.

For more information please visit

About CardioDx
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit


Media Contact:
Nicole Osmer